A. Kaushik

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models

This study evaluates how hyaluronidase affects the release and pharmacokinetics of a long-acting injectable drug in mice and rats.

Salmonella Typhimurium effector SseI regulates host peroxisomal dynamics to acquire lysosomal cholesterol for better intracellular growth

The paper shows Salmonella effector SseI recruits peroxisomes to SCVs, activates ARF-1, and facilitates cholesterol transport for bacterial growth.

Conformational dynamics of cohesin/Scc2 loading complex are regulated by Smc3 acetylation and ATP binding

This study identifies how Smc3 acetylation and ATP binding regulate the dynamic conformations of the cohesin/Scc2 complex during chromosome loading.

In-vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma

The paper identifies multiple glutamine metabolism pathways in ccRCC tumorgrafts and shows that targeting amidotransferase activity reduces tumor growth.

In vitro activity of bedaquiline and imipenem against actively growing, nutrient-starved, and intracellular Mycobacterium abscessus

This study evaluates the in vitro activity of bedaquiline and imipenem against M. abscessus under different growth conditions, finding varying interactions between the drugs.

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics Against Mycobacterium abscessus Complex Clinical Isolates

Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection

This study evaluates a long-acting injectable bedaquiline formulation in a mouse model of latent tuberculosis, showing its efficacy with fewer doses compared to daily oral regimens.

In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates

This study evaluates the in vitro activity of β-lactamase inhibitors relebactam and vaborbactam with β-lactams against MABC clinical isolates, showing improved anti-MABC activity.